查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1499967

全球多发性硬化症市场评估：依 MS 类型、药物类别、诊断、给药途径、最终用户、地区、机会、预测（2017-2031 年）

Multiple Sclerosis Market Assessment, By Type of MS, By Drug Class, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球多发性硬化症市场规模预计将从 2023 年的 271.2 亿美元增至 2031 年的 378.1 亿美元，预计 2024-2031 年的复合年增长率为 4.24%。该市场受到多种因素的影响，包括政府举措、技术进步、对免疫抑制剂不断增长的需求、復发缓解性疾病的治疗以及对研发的日益关注。

世界各国政府正在采取多项措施来指导和教育人们如何治疗多发性硬化症，并提高公众对该疾病的认识。这些措施有助于加速全球多发性硬化症市场的扩张并支持区域发展。基于人工智慧的工具越来越多地被使用，扰乱了全球多发性硬化症市场。这些工具彻底改变了新药的开发，并改变了全球多发性硬化症市场。研究能力的增强正在推动治疗多发性硬化症的先进精准药物的开发。

全球多发性硬化症市场的成长受到治疗各种类型多发性硬化症的免疫抑製药物需求不断增长的影响。这些药物在改变免疫系统反应、减少发炎和延缓老化过程中发挥作用。全球多发性硬化症市场受到治疗復发缓解型多发性硬化症药物需求的增加所推动。多家公司致力于开发客製化治疗方法，透过解决与这种疾病相关的特定课题和症状来满足需求。全球多发性硬化症市场的领导者正在优先考虑透过研究和开发改善症状治疗，以改善疾病的进展。这些努力正在推动疾病管理创新技术的发展。

例如，2024年5月，韦恩州立大学医学院分子医学和遗传学中心教授兼副主任、儿科和神经病学教授Alexander Gow博士宣布，他被诊断出可能患有多发性硬化症为了找出原因，我们从NMSS（National Multiple Sclerosis Society）获得了为期三年的研究经费644,827 美元。

政府推动市场成长的举措

近年来，由于世界各国政府的积极参与，全球多发性硬化症市场呈现成长态势。政府正在积极采取多项措施来促进市场发展，包括促进行业的研究和开发、传播对多发性硬化症的认识以及组织各种教育计划。透过这些举措，政府希望提高人们对该疾病的认识，增加患者获得创新治疗的机会，并改善卫生系统的基础设施。这些努力对于推动市场成长和满足未满足的患者需求至关重要，同时培养创新解决方案以实现更好的疾病管理。

例如，着名的全国性非营利组织 MS Australia 讚扬了政府在 2024 年 5 月资助健康和医学研究的承诺，但指出神经病学研究没有获得足够的资金或对其没有得到关注表示担忧。该组织表示，像多发性硬化症（MS）这样的神经系统疾病应该成为国家医学研究的重点优先事项，并呼吁成立Neurological Research Mission。

技术进步推动市场

人工智慧的使用正在推动更先进、更有效的多发性硬化症治疗方法的开发，也是推动全球多发性硬化症市场成长的主要因素。这些先进的仪器正在支持特定疾病药物的开发，以帮助制定满足每位患者需求的客製化治疗计划。人工智慧可以极大地帮助分析 MRI 扫瞄等放射影像，这对于诊断多发性硬化症至关重要。

本报告研究和分析了全球多发性硬化症市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第1章 研究方法论

第2章 专案范围与定义

第3章 执行摘要

第4章 全球多发性硬化症市场展望（2017-2031）

  • 市场规模及预测
    • 金额
    • 数量
  • 依 MS 类型
    • 临床孤立症候群
    • 復发缓解型多发性硬化症
    • 继发性进行性多发性硬化症
    • 原发性进行性多发性硬化症
  • 依药物类别
    • 免疫调节
    • 免疫抑製剂
    • 干扰素
    • 其他
  • 透过诊断
    • 验血
    • 脊椎穿刺
    • 核磁共振成像
    • 诱发电位测试
  • 依给药途径
    • 注射
    • 口服
  • 依最终用户
    • 医院
    • 专科诊所
    • 居家护理
    • 其他
  • 依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第5章 全球多发性硬化症市场展望：依地区（2017-2031）

  • 北美
    • 市场规模及预测
    • 依 MS 类型
    • 依药物类别
    • 透过诊断
    • 依给药途径
    • 依最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 南美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第6章 市场测绘（2023）

  • 依 MS 类型
  • 依药物类别
  • 透过诊断
  • 依给药途径
  • 依最终用户
  • 依地区

第7章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第8章 市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第9章 监理架构与创新

  • 专利情况
  • 创新/新技术

第10章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT 分析（5 家市场公司）
  • 专利分析（如果适用）

第11章 价格分析

第12章 案例研究

第13章 主要公司展望

  • Biogen Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Mylan NV

第14章 战略建议

第15章 关于我们公司、免责声明

Product Code: MX11505

Global multiple sclerosis market is projected to witness a CAGR of 4.24% during the forecast period 2024-2031, growing from USD 27.12 billion in 2023 to USD 37.81 billion in 2031. Various factors are shaping the global multiple sclerosis market, such as initiatives undertaken by the governments of different countries, technological advancements, increasing demand for immunosuppressant drugs, treatment of relapsing-remitting disease, and growing focus on research and development.

Governments across the world have been taking numerous initiatives to guide and educate people about the treatments used to manage multiple sclerosis and to promote public awareness of the disease. These initiatives help to speed up the expansion of the global multiple sclerosis market and support regional development. Tools based on artificial intelligence are increasingly being used and have disrupted the global multiple sclerosis market. These tools have transformed the global multiple sclerosis market by leading to changes in the development of novel medicines. There has been an increase in the research capacity, leading to the development of more advanced and precise drugs for treating multiple sclerosis.

The growth of global multiple sclerosis market is being influenced by the rising demand for immunosuppressant drugs for treating different types of multiple sclerosis. These medications alter the immune system's response and are responsible for reducing inflammation and slowing down the aging process. The global multiple sclerosis market is being driven by the increasing demand for the drugs available to treat relapsing-remitting multiple sclerosis. Various companies focus on developing customized treatments to fulfill the demand by addressing specific difficulties and symptoms associated with the disease. Key players in the global multiple sclerosis market prioritize improving the disease's progression by focusing on improving symptomatic management through research and development. These initiatives are bolstering the development of innovative technologies for disease management.

For instance, in May 2024, Alexander Gow, Ph.D., professor and associate director of the Center for Molecular Medicine and Genetics, as well as professor of pediatrics and neurology at Wayne State University School of Medicine, was granted USD 644,827 for three years by the NMSS (National Multiple Sclerosis Society) to find the possible causes of multiple sclerosis.

Government Initiatives to Drive the Market Growth

Lately, the global multiple sclerosis market has been observing growth due to the active involvement of governments across the world. Governments are proactively taking several steps to promote the development of the market, such as boosting research and development in the industry, spreading awareness about multiple sclerosis, and organizing various educational programs. Through these initiatives, the government wants to increase awareness about the disease and make innovative treatments accessible to patients while improving the healthcare system's infrastructure. Such initiatives aid in propelling market growth and are essential in meeting the patient's unmet needs while promoting innovative solutions for better disease management.

For instance, MS Australia, a prominent national non-profit organization, applauded the government's commitment to fund health and medical research in May 2024 but expressed concern that neurological research is not receiving enough funding or attention. The organization called for the creation of a Neurological Research Mission stated that neurological disorders such as multiple sclerosis (MS) should be a key national priority for medical research.

Technological Advancements to Facilitate the Market

The use of artificial intelligence is facilitating the development of more advanced and efficient treatments for multiple sclerosis, thus being a major factor driving the growth of the global multiple sclerosis market. These advanced instruments support the development of disease-specific medications that help create customized treatment plans that meet the requirements of every patient. AI can be highly useful in analyzing radiological images, such as magnetic resonance imaging (MRI) scans, which are essential in diagnosing multiple sclerosis.

For instance, in May 2024, Head Diagnostics (Dublin, Ireland) and the Royal College of Surgeons in Ireland collaborated on clinical research to improve the monitoring and assessment of Multiple Sclerosis (MS) using cutting-edge technologies. The study, which was started in conjunction with World MS Day, aims to provide more impartiality in the evaluation of the condition by investigating the application of novel digital biomarkers to monitor disease.

Increasing Demand for Immunosuppressant Drugs

Immunosuppressant drugs are excessively used globally as they tend to protect the myelin sheath from the harmful effects of the overactive immune system. These drugs suppress the immune system's reaction and reduce inflammation in the myelin sheath. Immunosuppressant drugs provide adequate results against the disease by prolonging the course of the disease. There has been a significant rise in demand for these drugs in the global multiple sclerosis market due to the rapid rise in the prevalence of the disease.

In February 2024, Roche Pharma introduced Ocrelizumab, sold under the brand name Ocrevus, in the Indian market for the management of multiple sclerosis and the slow progression of disability. Ocrevus is an immunosuppressant drug made from artificially produced antibodies obtained from human cells.

Treatment of Relapsing-Remitting MS

The increase in demand for drugs used to treat relapsing-remitting multiple sclerosis is a major factor driving the growth of the global multiple sclerosis market. Recently, several major companies have been making efforts to increase the efficiency of the drugs used to treat relapsing-remitting multiple sclerosis through improvements in drug research. Alternative treatment options are available to the patients through immunomodulators and immunosuppressants. These alternatives are highly efficient in treating disease as they can address the personalized requirements of patients. Pharmaceutical companies are expected to diverge their products related to RRMS (relapsing-remitting multiple sclerosis) due to the growing number of cases.

For instance, the U.S. Patent and Trademark Office (USPTO) granted a new patent covering the use of Ponvory (ponesimod), an oral medication approved for treating relapsing forms of multiple sclerosis (MS), spanning nearly two decades, according to a January 2024 announcement from Vanda Pharmaceuticals, a well-known international biopharmaceutical company. The recently granted patent particularly covers techniques for lowering clinical management events both before and during Ponvory treatment, as well as strategies for resuming medication following missing doses.

European Markets are Growing at a Fast Pace

Europe's multiple sclerosis market has observed significant changes. Companies focus on manufacturing new products through research and development, raising public knowledge of multiple sclerosis and its therapies. The global multiple sclerosis market participants focus on continuous clinical trials to improve the efficacy of the medications. The market is expanding due to pharmaceutical companies and concerned authorities meeting patient requirements, surpassing challenges such as diagnosis limitations.

For instance, in February 2024, Neuraxpharm Group, a European specialty pharmaceutical company focused on treating CNS disorders, announced the launch of BRIUMVI (ublituximab) in Europe. In adult patients, BRIUMVI is used for the treatment of relapsing multiple sclerosis with active disease. The drug was first launched in Germany and then in the rest of Europe.

Future Market Scenario (2024 - 2031F)

Cost-effective solutions such as biosimilars will reshape treatment options in the global multiple sclerosis market.

Advancements and growing demand for precision medicine will drive the need for personalized treatment options in the global multiple sclerosis market.

The integration of digital health solutions, such as telemedicine and remote monitoring, will influence the global multiple sclerosis market.

Increase in innovations in regenerative therapies offer promise for the treatment, boosting the growth of the global multiple sclerosis market.

Key Players Landscape and Outlook

Collaborations and partnerships have played an integral role in the growth of the global multiple sclerosis market. These collaborations ensure that different perspectives are considered to fulfill the diverse nature of the requirements. Pharmaceutical firms, healthcare providers, and government organizations are the major stakeholders in the market. The wide representation guarantees that different viewpoints are considered, resulting in more thorough and efficient solutions. Patient participation and engagement in the research process are prioritized in many collaborations. The method guarantees that therapies are customized to address the unique requirements and worries of individuals suffering from multiple sclerosis.

To operate and develop digital health solutions for rare diseases and neurological diseases such as multiple sclerosis, Aptar Digital Health, a division of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing, and protection technologies, entered into an enterprise agreement with Biogen Inc. in February 2024. Under the terms of the transaction, Biogen gave Aptar Digital Health (Aptar) ownership of several digital health products.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Multiple Sclerosis Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type of MS
    • 4.2.1. Clinically Isolated Syndrome
    • 4.2.2. Relapsing-remitting MS
    • 4.2.3. Secondary Progressive MS
    • 4.2.4. Primary Progressive MS
  • 4.3. By Drug Class
    • 4.3.1. Immunomodulatory
    • 4.3.2. Immunosuppressant
    • 4.3.3. Interferon
    • 4.3.4. Others
  • 4.4. By Diagnosis
    • 4.4.1. Blood Tests
    • 4.4.2. Spinal tap
    • 4.4.3. MRI
    • 4.4.4. Evoked Potential Tests
  • 4.5. By Route of Administration
    • 4.5.1. Injectable
    • 4.5.2. Oral
  • 4.6. By End-user
    • 4.6.1. Hospitals
    • 4.6.2. Specialty Clinics
    • 4.6.3. Homecare
    • 4.6.4. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. Asia-Pacific
    • 4.7.4. South America
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Multiple Sclerosis Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type of MS
      • 5.1.2.1. Clinically Isolated Syndrome
      • 5.1.2.2. Relapsing-remitting MS
      • 5.1.2.3. Secondary Progressive MS
      • 5.1.2.4. Primary Progressive MS
    • 5.1.3. By Drug Class
      • 5.1.3.1. Immunomodulatory
      • 5.1.3.2. Immunosuppressant
      • 5.1.3.3. Interferon
      • 5.1.3.4. Others
    • 5.1.4. By Diagnosis
      • 5.1.4.1. Blood Tests
      • 5.1.4.2. Spinal tap
      • 5.1.4.3. MRI
      • 5.1.4.4. Evoked Potential Tests
    • 5.1.5. By Route of Administration
      • 5.1.5.1. Injectable
      • 5.1.5.2. Oral
    • 5.1.6. By End-user
      • 5.1.6.1. Hospitals
      • 5.1.6.2. Specialty Clinics
      • 5.1.6.3. Homecare
      • 5.1.6.4. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
        • 5.1.7.1.1. By Value
        • 5.1.7.1.2. By Volume
      • 5.1.7.2. By Type of MS
        • 5.1.7.2.1. Clinically Isolated Syndrome
        • 5.1.7.2.2. Relapsing-remitting MS
        • 5.1.7.2.3. Secondary Progressive MS
        • 5.1.7.2.4. Primary Progressive MS
      • 5.1.7.3. By Drug Class
        • 5.1.7.3.1. Immunomodulatory
        • 5.1.7.3.2. Immunosuppressant
        • 5.1.7.3.3. Interferon
        • 5.1.7.3.4. Others
      • 5.1.7.4. By Diagnosis
        • 5.1.7.4.1. Blood Tests
        • 5.1.7.4.2. Spinal tap
        • 5.1.7.4.3. MRI
        • 5.1.7.4.4. Evoked Potential Tests
      • 5.1.7.5. By Route of Administration
        • 5.1.7.5.1. Injectable
        • 5.1.7.5.2. Oral
      • 5.1.7.6. By End-user
        • 5.1.7.6.1. Hospitals
        • 5.1.7.6.2. Specialty Clinics
        • 5.1.7.6.3. Homecare
        • 5.1.7.6.4. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type of MS
  • 6.2. By Drug Class
  • 6.3. By Diagnosis
  • 6.4. By Route of Administration
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Biogen Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Merck & Co. Inc.
  • 13.3. Novartis AG
  • 13.4. Pfizer, Inc.
  • 13.5. Sanofi SA
  • 13.6. Teva Pharmaceutical Industries Ltd
  • 13.7. Bristol-Myers Squibb Company
  • 13.8. F. Hoffmann-La Roche Ltd
  • 13.9. Johnson & Johnson
  • 13.10. Mylan NV

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 4. Global Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 5. Global Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 6. Global Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 7. Global Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Multiple Sclerosis Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 12. North America Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 13. North America Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 14. North America Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 15. North America Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 20. United States Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 21. United States Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 22. United States Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 23. United States Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 27. Canada Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 28. Canada Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 29. Canada Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 30. Canada Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 34. Mexico Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 35. Mexico Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 36. Mexico Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37. Mexico Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 41. Europe Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. Europe Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 43. Europe Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Europe Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 49. Germany Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 50. Germany Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 51. Germany Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 52. Germany Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 56. France Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. France Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 58. France Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 59. France Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 63. Italy Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 64. Italy Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 65. Italy Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 66. Italy Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 70. United Kingdom Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 71. United Kingdom Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 72. United Kingdom Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. United Kingdom Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 77. Russia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 78. Russia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 79. Russia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Russia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 84. Netherlands Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. Netherlands Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 86. Netherlands Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Netherlands Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 91. Spain Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 92. Spain Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 93. Spain Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Spain Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 98. Turkey Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 99. Turkey Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 100. Turkey Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 101. Turkey Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 105. Poland Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 106. Poland Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 107. Poland Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 108. Poland Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 112. South America Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 113. South America Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 114. South America Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. South America Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 120. Brazil Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 121. Brazil Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 122. Brazil Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 123. Brazil Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 127. Argentina Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 128. Argentina Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 129. Argentina Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. Argentina Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 134. Asia-Pacific Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Asia-Pacific Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 136. Asia-Pacific Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Asia- Pacific Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 139. India Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 142. India Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 143. India Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 144. India Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. India Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 149. China Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 150. China Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 151. China Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 152. China Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 156. Japan Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 157. Japan Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 158. Japan Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 159. Japan Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 163. Australia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 164. Australia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 165. Australia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. Australia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 170. Vietnam Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 171. Vietnam Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 172. Vietnam Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Vietnam Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 177. South Korea Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 178. South Korea Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 179. South Korea Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. South Korea Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 184. Indonesia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 185. Indonesia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 186. Indonesia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 187. Indonesia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 191. Philippines Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 192. Philippines Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 193. Philippines Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 194. Philippines Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 198. Middle East & Africa Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 199. Middle East & Africa Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 200. Middle East & Africa Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 201. Middle East & Africa Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Multiple Sclerosis Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 206. Saudi Arabia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 207. Saudi Arabia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 208. Saudi Arabia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 209. Saudi Arabia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 213. UAE Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 214. UAE Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 215. UAE Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 216. UAE Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
  • Figure 220. South Africa Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
  • Figure 221. South Africa Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
  • Figure 222. South Africa Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
  • Figure 223. South Africa Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Type of MS Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023